ATAD2 and nonpapillary renal cell carcinoma: ATAD2 facilitates the development of clear cell renal cell carcinoma (ccRCC) and resistance to tyrosine kinase inhibitors (TKIs) by collaborating with SSY-Box transcription factor 9 (SOX9) to form super-enhancers in ccRCC cancer stem cells (CSCs).